Unpacked Clinical Readouts, Explored Novel Targets, Utilized 3D Models, and Identified Translatable Biomarkers to Herald the Next Generation of Anti-Inflammatory Drugs in the CNS.
With Vigil, Alector, Denali and Novartis trailblazed in TREM2 approaches for Alzheimer’s Disease, and Roche, Sanofi, Biogen & Novartis having pushed forward BTKi’s development, the neuroinflammation field was eager to unpack new clinical readouts to inform the future of drug development in the CNS.
Refining the utility of GFAP and NFL as translatable biomarkers, validating exploratory markers, novel pathways, modalities, and targets beyond TREM2 and BTK was crucial in developing the next generation of neuroinflammatory-targeted therapeutics to address the breadth of immunopathology in Alzheimer’s, Parkinson’s, ALS, MS, Huntington’s, CIDP, and more.
Annually uniting 100+ CNS scientists, directors, and lab heads from Alector, Biogen, Eisai, EMD Serono, Merck, Muna, Therapeutics, Novartis, Roche, Sanofi, Takeda, Vigil Neuroscience and many more, the 7th Neuroimmunology Drug Development Summit was biopharma’s must-attend forum for learning, benchmarking, and debating cutting-edge mechanistic insights into glial biology, TREM2, and BTKi clinical learnings to optimize neuroimmunology translation and develop transformative therapeutics for neurological disorders.
World-Class Speaker Faculty Includes:
Previously Attending Companies Include:
Hear what past attendees had to say:
“A very focused conference that gives opportunity to big pharma as well as new emerging biotech to share progress in their drug development programs. A great opportunity for networking to keep updated with industry leaders and for potential collaborations. ”
Valentina Di Caro, Director, Research, Cognition Therapeutic
“The Neuroimmunology conference brings together leading experts in the field of neuroimmunology and neuroinflammation, allowing an open forum for critical discussions on the latest nonclinical, clinical and translational data in the field. The variety of focused sessions, in-depth discussions and networking opportunities allow for rich and insightful conversations from peers across academia and industry.”
Thomas Tamsett, Director of Neuroscience, EMD Serono
“The meeting is an excellent neuroimmunology-dedicated event to present novel therapeutic approaches and stay up to date with the field. ”
Kuti Brauch, Vice President, Research & Development, ImmunoBrain
“The format of this industry-focused conference allows easy and open discussion on assays, projects in the Neuroinflammation field with peers which is not always feasible in larger conferences. ”
Jean-Philippe Courade, Chief Scientific Officer, Discoveric Bio
2025 Partners
Next Events in the World CNS Series
